Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy

Azzurra Orlandi, Maria Chiara Paolino, Pasquale Striano, Pasquale Parisi

Research output: Contribution to journalReview articlepeer-review


Introduction: Although novel antiepileptic drugs (AEDs) have been recently released, the issue of drug resistance in epileptic patients remains unsolved and largely unpredictable. Areas covered: We aim to assess the clinical impact of genetic variations that may influence the efficacy of medical treatment in epilepsy patients. Indeed, many genes, including genes encoding drug transporters (ABCB1), drug targets (SCN1A), drug-metabolizing enzymes (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins, may regulate the mechanisms of drug resistance in epilepsy. This review specifically focuses on the ABC genes, which encode multidrug resistance-associated proteins (MRPs) and may reduce the blood–brain barrier penetration of anticonvulsant AEDs. Expert opinion: Drug resistance remains a crucial problem in epilepsy patients. Pharmacogenomic studies may improve our understanding of drug responses and drug resistance by exploring the impact of gene variants and predicting drug responses and tolerability.

Original languageEnglish
Pages (from-to)505-512
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number5
Publication statusPublished - May 4 2018


  • antiepileptic drugs
  • Genetic polymorphisms
  • refractory epilepsy
  • transporters

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy'. Together they form a unique fingerprint.

Cite this